Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Completed Phase 3 Interventional Results available

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965
View directory record Official record
Conditions
Psoriasis
Interventions
BI 695501, Humira
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 25, 2026, 12:17 AM EDT
Withdrawn Phase 4 Interventional

Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

NCT00832364
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Acitretin (also called U0279), Placebo, Etanercept
Drug · Biological
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Francisco, California • Louisville, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 25, 2026, 12:17 AM EDT
Recruiting Phase 3 Interventional

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Ustekinumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
3,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
122
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 12:17 AM EDT
Terminated Phase 1 Interventional

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

NCT01261767
View directory record Official record
Conditions
Inflammation, Psoriasis
Interventions
anti-IL-20, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Skokie, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

NCT01484964
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 25, 2026, 12:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

NCT03835481
View directory record Official record
Conditions
Psoriasis
Interventions
BI 730357, Placebo to match BI 730357
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Not applicable Interventional

Study of the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy

NCT00537212
View directory record Official record
Conditions
Psoriasis, Weight Loss, Diet
Interventions
The South Beach Diet, The Ornish Diet, Control Group
Other
Lead sponsor
Bagel, Jerry, M.D.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 25, 2026, 12:17 AM EDT
Not listed Phase 4 Interventional

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

NCT05135312
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis, Psoriatic Nail
Interventions
Etanercept, OCT
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06602219
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LY4100511, Placebo
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Bryant, Arkansas • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Chronic Pain From Arthritis

NCT03008590
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 3 Interventional

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04175613
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 25, 2026, 12:17 AM EDT
Not listed No phase listed Observational

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

NCT05084417
View directory record Official record
Conditions
Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions
N/A This is an observational study
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 25, 2026, 12:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions

NCT03198390
View directory record Official record
Conditions
Atopic Dermatitis, Hidradenitis Suppurativa, Contact Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 25, 2026, 12:17 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis

NCT05195814
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis

NCT01836939
View directory record Official record
Conditions
Psoriasis
Interventions
TSO 2500, TSO 7500
Drug
Lead sponsor
Mark Lebwohl
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 2 Interventional

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

NCT03065556
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Solution, Vehicle Solution
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 25, 2026, 12:17 AM EDT
Not listed Phase 4 Interventional

The Maintenance Effect of Enstilar Foam in Combination With Otezla

NCT04555707
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast 30mg, calcipotriene and betamethasone dipropionate
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 25, 2026, 12:17 AM EDT
Withdrawn Phase 2 Interventional

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy

NCT01200264
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
apremilast
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 25, 2026, 12:17 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

NCT02173392
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
6
States / cities
Glendale, California • Aventura, Florida • Saint Paul, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 25, 2026, 12:17 AM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 25, 2026, 12:17 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

NCT00373516
View directory record Official record
Conditions
Psoriasis
Interventions
Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Santa Rosa, California • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 25, 2026, 12:17 AM EDT
Recruiting Not applicable Interventional

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT07180537
View directory record Official record
Conditions
Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions
Creating Health Online Course, Delayed access to Creating Health Online Course
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 12:17 AM EDT